Cargando…
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Antibody-drug conjugates (ADCs) are a promising class of immunotherapies with the potential to specifically target tumor cells and ameliorate the therapeutic index of cytotoxic drugs. ADCs comprise monoclonal antibodies, cytotoxic payloads with inherent antitumor activity, and specialized linkers co...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180036/ https://www.ncbi.nlm.nih.gov/pubmed/34090506 http://dx.doi.org/10.1186/s13045-021-01097-z |